Long‐Term Vascular Responses to Resolute® and Xience V® Polymer‐Based Drug‐Eluting Stents in a Rabbit Model of Atherosclerosis

Hoymans, Vicky Y.; Dyck, Christophe J. Van; Haine, Steven; Frederix, Geert; Fransén, Erik; Timmermans, Jean‐Pierre; Vrints, Christiaan J.

doi:10.1111/joic.12128

Cited by 7 publications

(3 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It was also recently reported by Holdaas and colleagues [44] that coronary artery intimal thickening and the incidence of cardiac allograft vasculopathy were significantly reduced by everolimus therapy. In combination with other clinical studies [45][46][47] , it has been shown that everolimus-eluting stents are the optimal choice for preventing vascular restenosis and the occurrence of cardiac allograft vasculopathy (CAV) after heart transplant or other cardiac surgeries.…”

Section: Pharmacological Intervention Of Autophagy In the Treatment Omentioning

confidence: 99%

The roles of macrophage autophagy in atherosclerosis

Shao

Han

Zeng³

et al. 2016

Acta Pharmacol Sin

180

116

View full text Add to dashboard Cite

Although various types of drugs and therapies are available to treat atherosclerosis, it remains a major cause of mortality throughout the world. Macrophages are the major source of foam cells, which are hallmarks of atherosclerotic lesions. Consequently, the roles of macrophages in the pathophysiology of atherosclerosis are increasingly investigated. Autophagy is a self-protecting cellular catabolic pathway. Since its discovery, autophagy has been found to be associated with a variety of diseases, including cardiovascular diseases, malignant tumors, neurodegenerative diseases, and immune system disorders. Accumulating evidence demonstrates that autophagy plays an important role in inhibiting inflammation and apoptosis, and in promoting efferocytosis and cholesterol efflux. These facts suggest the induction of autophagy may be exploited as a potential strategy for the treatment of atherosclerosis. In this review we mainly discuss the relationship between macrophage autophagy and atherosclerosis and the molecular mechanisms, as well as the recent advances in targeting the process of autophagy to treat atherosclerosis.

show abstract

Section: Pharmacological Intervention Of Autophagy In the Treatment Omentioning

confidence: 99%

The roles of macrophage autophagy in atherosclerosis

Shao

Han

Zeng³

et al. 2016

Acta Pharmacol Sin

180

116

View full text Add to dashboard Cite

show abstract

“…Nonetheless, a number of studies have assessed DES efficacy in this model and have shown important similarities to many aspects of the human response to stenting. 21 , 74…”

Section: Modelling Impact Of Atherosclerosis On Drug Release and Distmentioning

confidence: 99%

Modelling the Impact of Atherosclerosis on Drug Release and Distribution from Coronary Stents

et al. 2015

View full text Add to dashboard Cite

Although drug-eluting stents (DES) are now widely used for the treatment of coronary heart disease, there remains considerable scope for the development of enhanced designs which address some of the limitations of existing devices. The drug release profile is a key element governing the overall performance of DES. The use of in vitro, in vivo, ex vivo, in silico and mathematical models has enhanced understanding of the factors which govern drug uptake and distribution from DES. Such work has identified the physical phenomena determining the transport of drug from the stent and through tissue, and has highlighted the importance of stent coatings and drug physical properties to this process. However, there is limited information regarding the precise role that the atherosclerotic lesion has in determining the uptake and distribution of drug. In this review, we start by discussing the various models that have been used in this research area, highlighting the different types of information they can provide. We then go on to describe more recent methods that incorporate the impact of atherosclerotic lesions.

show abstract

“…Polymer‐related causes were ascribed to release of polymer by‐products or release of degradation products from low molecular weight degradable polymers. Preclinical studies comparing the same two commercial DES coated with two different durable polymers have shown a consistent difference in the inflammatory response to the implants . As the drugs and stent platforms used are well proven, a potential explanation lies in differences in the biocompatibility or stability of the durable coatings.…”

Section: Introductionmentioning

confidence: 99%

Evaluation of chemical stability of polymers of XIENCE everolimus‐eluting coronary stents in vivo by pyrolysis‐gas chromatography/mass spectrometry

et al. 2017

View full text Add to dashboard Cite

The polymers poly(vinylidene fluoride-co-hexafluoropropylene) (PVDF-HFP) and poly(n-butyl methacrylate) (PBMA) are employed in manufacturing the XIENCE family of coronary stents. PBMA serves as a primer and adheres to both the stent and the drug coating. PVDF-HFP is employed in the drug matrix layer to hold the drug everolimus on the stent and control its release. Chemical stability of the polymers of XIENCE stents in the in-vivo environment was evaluated by pyrolysis-gas chromatography with mass spectrometry (Py-GC/MS) detection. For this evaluation, XIENCE stents explanted from porcine coronary arteries and from human coronary artery specimens at autopsy after 2-4 and 5-7 years of implantation, respectively, were compared to freshly manufactured XIENCE stents (controls). The comparison of pyrograms of explanted stent samples and controls showed identical fragmentation fingerprints of polymers, indicating that PVDF-HFP and PBMA maintained their chemical integrity after multiple years of XIENCE coronary stent implantation. The findings of the present study demonstrate the chemical stability of PVDF-HFP and PBMA polymers of the XIENCE family of coronary stents in the in-vivo environment, and constitute a further proof of the suitability of PVDF-HFP as a drug carrier for the drug eluting stent applications. © 2017 Wiley Periodicals, Inc. J Biomed Mater Res Part B: Appl Biomater, 106B: 1721-1729, 2018.

show abstract

Long‐Term Vascular Responses to Resolute® and Xience V® Polymer‐Based Drug‐Eluting Stents in a Rabbit Model of Atherosclerosis

Cited by 7 publications

References 28 publications

The roles of macrophage autophagy in atherosclerosis

The roles of macrophage autophagy in atherosclerosis

Modelling the Impact of Atherosclerosis on Drug Release and Distribution from Coronary Stents

Evaluation of chemical stability of polymers of XIENCE everolimus‐eluting coronary stents in vivo by pyrolysis‐gas chromatography/mass spectrometry

Contact Info

Product

Resources

About